Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis

Ben Davidson 1,2 · Lilach Kleinberg 1 · Ida Marie Børresen 1 · Froysl Slettevoll 3 · Anne Fangberget 3 · Dunia Hindosh 4 · Ane Gerda Zahl Eriksson 5 · Bodil Bjerkehagen 1,2,6

Received: 11 December 2020 / Revised: 31 January 2021 / Accepted: 7 February 2021 / Published online: 17 February 2021 © The Author(s) 2021

Abstract
Ectomesenchymoma is an exceedingly rare biphasic malignant tumor characterized by the presence of mesenchymal and neuroectodermal elements. The majority of patients are infants or children. We describe the first case of this entity diagnosed as a primary uterine tumor. A 72-year-old female presented with post-menopausal bleeding. Dilatation and curettage showed irregular mesenchymal proliferation of uncertain nature. In the hysterectomy specimen, a myxoid spindle cell tumor with areas of skeletal muscle and neural differentiation was found in the uterus, with direct invasion of the small intestine, and biphasic differentiation into rhabdomyosarcoma and ganglioneurolastoma was unequivocally seen in a lymph node metastasis. The morphological findings were validated by immunohistochemistry. Massive parallel sequencing identified TP53, PTEN, and DICER1 mutations in the tumor. This report describes the presence of ectomesenchymoma in an unusual primary organ and in an uncharacteristic age and presents novel data regarding the genetic characteristics of this tumor.

Keywords Ectomesenchymoma · Uterus · Immunohistochemistry · Massive parallel sequencing · Metastasis

Introduction
Ectomesenchymoma is an exceedingly rare biphasic malignant tumor characterized by the presence of mesenchymal and neuroectodermal elements. The former manifests as rhabdomyosarcoma (RMS), which may have botryoid, spindle cell and myxoid, or primitive round cell pattern. The neuroectodermal component is neuroblastic, with variable degree of differentiation, manifesting as neuroblastoma, ganglioneuroblastoma, or ganglioneuroma. The majority of patients are infants or children younger than 15 years, often <5 years, with a male-to-female ratio of 1.38. Common primary sites include the pelvis/perineum, urogenital organs, and intra-abdominal or retroperitoneal soft tissue. A minority of tumors is located at the head and neck region, the extremities, and the mediastinum. Tumors have been reported to have a diameter of 3–18 cm, with tan color and frequent hemorrhage and necrosis. Treatment and outcomes are comparable to those of patients with embryonal RMS. Parameters associated with favorable outcome include age ≤3 years, size <10 cm, and superficial location [1].

To the best of our knowledge, ectomesenchymoma has not been reported as a primary uterine tumor. We report a rare case of this malignancy presenting at this anatomic location, at an unusual age. We additionally report on the genomic profile of this tumor.

Case report
Clinical presentation
A 72-year-old female presented to her local gynecologist with post-menopausal bleeding. A uterine tumor was found, clinically
diagnosed as leiomyoma. Her past medical history included insulin-dependent diabetes mellitus, hypertension, and hypercholesterolemia, with no previous gynecologic history and 6 term deliveries. Following inconclusive diagnosis after dilatation and curettage (see below), the patient was referred to the Department of Gynecologic Oncology at the Norwegian Radium Hospital. At presentation, the patient reported continuous pinkish vaginal discharge and loss of energy and possibly weight over the last few weeks, with no abdominal discomfort. Her physical examination was unremarkable, performance status ECOG 0-1. Pelvic examination revealed a large, non-painful immobile pelvic/abdominal mass. CA125 was within normal range (24U/mL), and HE4 was elevated (188 pmol/L).

Chest/abdomen/pelvic CT and pelvic MRI demonstrated significantly enlarged uterus with a large (11.6 × 11.9 × 13.4 cm), heterogeneous tumor and enlarged iliac lymph nodes. The uterine tumor infiltrated the myometrium and breached the serosa, with suspected invasion of adjacent small bowel. CT demonstrated an air-filled area thought to represent fistula to the adjacent small bowel (Fig. 1). CT also showed pulmonary nodules up to 6 mm in diameter suspicious for metastasis.

The patient was assessed to be a surgical candidate with good performance status, and complete resection of the abdominal disease was deemed feasible. Surgery consisted of en bloc resection of the uterus, adnexae, and two small bowel loops adherent to the uterus, as well as removal of enlarged pelvic lymph nodes. At the end of surgery, there was no gross residual disease intra-abdominally, with clear surgical margins achieved and no tumor spillage.

**Histopathology**

In the preoperative curettage specimen, a partly myxoid irregular spindle cell proliferation, with areas of necrosis and pronounced inflammation, was observed (Fig. 2a). Immunostaining showed expression of vimentin and CD10, negative staining for pan-cytokeratin AE1/AE3, desmin, caldesmon, SMA, actin, ALK, and p16. p53 showed wild-type pattern (data not shown). No conclusive diagnosis of malignancy or typing of the process was deemed possible.

Gross examination of the surgical specimen showed a uterine tumor measuring 12.5 cm in largest diameter, with areas of hemorrhage and necrosis. Breach of the uterine serosa and invasion of adjacent small intestine was evident. Microscopically, a spindle cell proliferation reminiscent of the curettage specimen was seen, with myxoid areas and foci of necrosis (Fig. 2b). Cells with abundant eosinophilic cytoplasm suggestive of the skeletal muscle differentiation (Fig. 2c) and epithelioid acini, trabeculae, and rosette-like structures (Fig. 2d) were additionally seen, as were areas of increased, focally severe atypia (Fig. 2e) and evidence of cartilage formation (Fig. 2f). Mitotic counts were 8/10 HPF, some atypical.

As assessed clinically, radiologically and at gross examination, the tumor invaded the small intestine (Fig. 3a), where the predominant histology was of the abovementioned epithelioid acini, trabeculae, and rosette-like structures (Fig. 3b), as well as clusters of mature ganglion cells (Fig. 3c). Neural, predominantly immature differentiation was confirmed by positive immunostaining for synaptophysin (Fig. 3d) and SALL4 (Fig. 3e), respectively, with only focally positive (<5%) CK8 expression and negative staining for Ber-EP4. Staining for chromogranin A (CGA) and OCT3/4 was negative.

Metastases were found in 2/6 removed lymph nodes, one in the left obturator region and one in the right external iliac region. In the former, unequivocal differentiation into ganglion cells (Fig. 3f) and skeletal muscle (Fig. 3g) was found, confirmed by positive immunostaining for synaptophysin (Fig. 3h), pan-neurofilament (NF; Fig. 3i), and CGA (Fig. 3j) in the neural cells; desmin (Fig. 3k) and Myf-4 (Fig. 3l) in the skeletal muscle cells. Both components were positive for vimentin. S100 staining was focally positive.

**Massive parallel sequencing**

DNA and RNA were extracted from sections of formalin-fixed, paraffin-embedded tissue (FFPE) using QIAamp
DNA FFPE Tissue Kit (Qiagen, Hilden, Germany), and RNeasy FFPE Kit (Qiagen), respectively. Tumor cell percentage in the sections was estimated at 90%. Targeted sequencing of 203 cancer-associated genes was performed using the Oncomine Childhood Cancer Research Assay on an Ion Torrent S5 Prime instrument (both from Thermo Fisher Scientific, Carlsbad, CA). Sequences were analyzed for mutations, copy number gain, and gene fusions using Ion Reporter Software v.5.10 (Thermo Fisher Scientific). DNA was additionally analyzed for TERT promoter mutations using Sanger sequencing.

Variant analysis revealed c.5428G>T; p.Asp1810Tyr DICER1 missense mutation, missense mutation in TP53 (c.730G>A; p.Gly244Ser), and two missense mutations in PTEN (c.376G>A; p.Ala126Thr and c.406T>C; p.Cys136Arg). No fusion genes, copy number gain, or TERT promoter mutations were detected. Microdissection of the RMS and neuroectodermal component, with repeat of the analysis, showed that all four mutations were more frequent in the neuroectodermal component (Supplementary Table 1).

**Follow-up**

CT of the chest/abdomen/pelvis 6 weeks postoperatively demonstrated pulmonary embolus, left-sided pleural effusion, and slight regression of the previously detected pulmonary nodules. New peritoneal thickening consistent with sarcomatosis was found. The patient was offered palliative chemotherapy. The patient has recently completed her second cycle of adjuvant chemotherapy, consisting of Doxorubicin (50 mg/m²) and Ifosfamide (5 g/m²). A decision has been made to continue with Doxorubicin monotherapy for the remaining cycles due to adverse events related to Ifosfamide. CT has been scheduled after her third cycle to assess chemotherapy response.
Discussion

The majority of patients diagnosed with ectomesenchymoma are pediatric [2–5]. Though isolated reports of tumors diagnosed in adults have been published [6, 7], the age of the patient in this report is exceptional. Similarly, whereas location of the primary tumor in the abdomen, pelvis, groin, perineum, paratesticular region, and vulva has been reported [2–5], ectomesenchymoma has not, to the best of our knowledge, been diagnosed as a primary uterine tumor to date. One possibility which cannot be entirely ruled out is that this tumor developed from a carcinocarcinoma. However, no epithelial component was found in this tumor despite extensive sampling.

Previous molecular studies of ectomesenchymoma have shown chromosomal changes (trisomy, polyploidy, or focal gains) involving chromosomes 2, 6, 8, 9, 10, 11, and 20, as well as t(12;15)(p12.3;q24.1) and t(1;12)(p32;p13) fusions, the latter with no rearrangement of ETV6 [8–12]. Griffin et al. found FOXO1 gene rearrangements by RT-PCR in three cases with alveolar RMS morphology, of which two involved PAX3-FOXO1 fusion, and one harbored PAX7-FOXO1 translocation [5]. Whole genome/exome sequencing studies of this tumor are to date limited to one report. Huang and co-workers studied seven ectomesenchymomas by RNA sequencing and detected HRAS, PTPRD, and FBXW7 mutations in six, two, and one cases, respectively. No fusion genes were found [4].

Fig. 3 Small intestine invasion and lymph node metastasis. Small intestine. a tumor invasion of the small intestine, b epithelioid acini, trabeculae, and rosette-like structures, suggesting neural differentiation, c mature ganglion cells, d positive immunostaining for synaptophysin; and e positive immunostaining for SALL4. Left obturator lymph node. f ganglion cells, g skeletal muscle, h–j positive immunostaining for synaptophysin (h), NF (i), and CGA (j) in the neural cells, k–l positive immunostaining for desmin (k) and Myf-4 (l) in the skeletal muscle cells.
In the present study, we performed sequencing analysis of FFPE material from the patient’s lymph node metastasis, which contained tumor with both skeletal muscle and neural differentiation. We report the presence of missense mutations in DICER1, TP53, and PTEN, the latter with two different mutations. Three of the four mutations have been reported to be pathogenic in various cancers (TP53: https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000376600.5; PTEN: https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000183726.6; DICER1: https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000933084.1), whereas the second PTEN mutation is of uncertain pathogenicity (https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000376600.5). The specific mutation found in the present tumor, c.5428G>T; p.Asp1810Tyr, has been reported in the uterine and cervical embryonal RMS and in uterine and peritoneal adenosarcoma, as well as in two embryonal RMS of unknown origin [13], reinforcing the link between eutomesenchymoma and embryonal RMS highlighted in the Huang paper [4]. Whether any of these tumors was an eutomesenchymoma in which the neural component was not sampled remains an open question.

In conclusion, the present study reports a primary eutomesenchymoma of the uterus, presenting at an
uncharacteristic age and anatomic site, with mutations in *DICER1*, *TP53*, and *PTEN*. This malignancy, as RMS, is generally associated with unfavorable outcome when diagnosed with distant spread, and its management may benefit from future molecular characterization.

**Supplementary Information** The online version contains supplementary material available at [https://doi.org/10.1007/s00428-021-03057-x](https://doi.org/10.1007/s00428-021-03057-x).

**Author contributions** Ane Gerda Zahl Eriksson operated the patient and provided the clinical data. Fridaysc Slettevoll, Anne Fangberget, and Dunia Hindosh performed the radiological assessment. Ben Davidson and Bodil Bjerkehagen performed the histopathological evaluation. Lilach Kleinberg and Ida Marie Børresen performed the molecular analysis and interpreted its results. The first draft of the manuscript was written by Ben Davidson and all authors commented on this version. The authors read and approved the final manuscript.

**Funding** Open access funding provided by University of Oslo (incl Oslo University Hospital).

**Declarations**

The patient signed an informed consent form approving the use of tissue for the present study and publication of the data, according to the guidelines of Oslo University Hospital.

**Conflict of interest** None declared

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material, changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material, changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material, changes were made.

**References**

1. WHO Classification of tumours editorial board (2020) 5th Edition, Volume 3: Soft Tissue and Bone Tumours. IARC: Lyon, pp 214-215.

2. Dantonello TM, Leuschner I, Vokuhl C, Gfoerer S, Schuck A, Kube S, Nathrath M, Bernbeck B, Kaatsch P, Pal N, Ljungman G, Bielack SS, Klinglebiel T, Kossicielkia E, CWS (2013) Malignant ectomesenchymoma in children and adolescents: report from the Cooperative Weichteilsarkom Studiengruppe (CWS). Pediatr Blood Cancer 60:224–229

3. Boue DR, Parham DM, Webber B, Crist WM, Qualman SJ (2000) Clinicopathologic study of ectomesenchymomas from Intergroup Rhabdomyosarcoma Study Groups III and IV. Pediatr Dev Pathol 3:290–300

4. Huang SC, Alaggio R, Sung YS, Chen CL, Zhang L, Kao YC, Agaram NP, Wexler LH, Antonescu CR (2016) Frequent HRAS mutations in malignant ectomesenchymoma: overlapping genetic abnormalities with embryonal rhabdomyosarcoma. Am J Surg Pathol 40:876–885

5. Griffin BB, Chou PM, George D, Jennings LJ, Arva NC (2018) Malignant ectomesenchymoma: series analysis of a histologically and genetically heterogeneous tumor. Int J Surg Pathol 26:200–212

6. Mahajan S, Suri V, Sharma MC, Kedia S, Sardana H, Nakra T (2019) Primary intracranial malignant ectomesenchymoma in an adult: report of a rare case and review of the literature. Neuropathology 39:200–206

7. Kao WT, Chiang YT, Tzou KY (2015) An adult paratesticular malignant ectomesenchymoma with post-operative flare-up of lung metastasis. Urol Case Rep 3:164–166

8. Floris G, Debiec-Rychter M, Wozniak A, Manfioletti G, De Wever I, Tallini G, Sciot R (2007) Malignant ectomesenchymoma: genetic profile reflects rhabdomyosarcomatous differentiation. Diag Mol Pathol 16:243–248

9. Kleinschmidt-DeMasters BK, Lovell MA, Donson AM, Wilkinson CC, Madden JR, Addo-Yobo SO, Lillehei KO, Foreman NK (2007) Molecular array analyses of 51 pediatric tumors shows overlap between malignant intracranial ectomesenchymoma and MPNST but not medulloblastoma or atypical teratoid rhabdoid tumor. Acta Neuropathol 113:695–703

10. Goldsby RE, Bruggers CS, Brothman AR, Sorensen PH, Beckwith JB, Pysher TJ (1998) Spindle cell sarcoma of the kidney with ganglionic elements (malignant ectomesenchymoma) associated with chromosomal abnormalities and a review of the literature. J Pediatr Hematol Oncol 20:160–164

11. Hajivassiliou CA, Carachi R, Simpson E, Patrick WJ, Young DG (1997) Ectomesenchymoma: one or two tumors? Case report and review of the literature. J Pediatr Surg 32:1351–1355

12. Howley S, Stack D, Morris T, McDermott M, Capra M, Betts D, O’Sullivan MJ (2012) Ectomesenchymoma with t(1;12)(p32;p13) evolving from embryonal rhabdomyosarcoma shows no rearrangement of ETV6. Hum Pathol 43:299–302

13. Warren M, Hiemzen MC, Schmidt R, Shows J, Cotter J, Toll S, Parham DM, Biegel JA, Mascarenhas L, Shah R (2020) Expanding the spectrum of dicer1-associated sarcomas. Mod Pathol 33:164–174

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.